From @Breakingviews: @aimeedonnellan explains how GSK hiving off its Advil making unit could lead to risky M&amp;A prospects as the company loses exclusivity on a molecule contained in four of its HIV drugs, by 2027  https://t.co/Ie7VEDRiku